MYOK News and Press, MyoKardia Inc. From 02/28/19

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter an...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

I am returning from a writing break to once again cover the stock that I have both followed and written about for the longest period of time, Cytokinetics ( CYTK ). Cytokinetics is a developmental biotech which has been working in the area of muscle biology for over 20 years. Unfortunately, th...

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Duke Energy Corporation (NYSE:DUK), VICI Properties Inc. (NYSE:VICI), ...

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as ...

MyoKardia (NASDAQ: MYOK ) announces that its four-year collaboration with Sanofi (NYSE: SNY ) aimed at hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) ended on December 31, 2018. The partnership will formally conclude on April 1 with MYOK regaining global rights to ...

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered unde...

MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$0.39 beats by $0.11 . More news on: MyoKardia, Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.&#x...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer,...